Agilon Health, Inc.

Agilon Health, Inc. (AGL) Market Cap

Agilon Health, Inc. has a market capitalization of $1.53B.

Price: $91.61

-5.14 (-5.31%)

Market Cap: 1.53B

NYSE · time unavailable

CEO: Timothy O'Rourke

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2021-04-15

Website: https://agilonhealth.com

Agilon Health, Inc. (AGL) - Company Information

Market Cap: 1.53B|Sector: Healthcare

Company Profile

Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.

Analyst Sentiment

35%
Underperform

From 18 Active Polls

1Y Forecast: $67.00

▼ -26.9% Potential Upside

Consensus Target Metrics

Low Bound

$16

Median

$49

High Bound

$141

Average

$67

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$67.00
▼ -26.86% Upside
Low Target
$16.00
-83% Risk
Median Target
$49.00
-47% Mid
High Target
$141.00
54% Max
Consensus
Hold
8 / 25 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,5281312864279521,7887831,6182,496
Enterprise Value ($M)1,422251492928221,6916331,5082,426
Price to Earnings Ratio (P/E)-4.041.10-0.37-0.95-2.3036.08-1.83-3.39-21.68
Price/Earnings-to-Growth Ratio (PEG)-0.04-0.3353.36-0.37
Price to Sales Ratio (P/S)0.260.090.180.300.681.170.511.111.68
Price to Book Ratio (P/B)8.380.722.251.392.333.571.662.813.69
Price to Free Cash Flow Ratio (P/FCF)-19.956.37-7.60-20.01-24.83-41.71195.92243.02-87.64
Enterprise Value to Sales (EV/Sales)0.020.090.200.591.100.421.041.64
Enterprise Value to EBITDA (EV/EBITDA)-4.170.71-0.83-2.89-8.61252.49-6.55-13.81-107.16
Debt to Equity Ratio0.310.180.290.120.100.080.090.080.07

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AGILON HEALTH (AGL) — Investment Overview

🧩 Business Model Overview

Agilon Health operates as a value-based care enablement platform that connects payers with independent physician practices through coordinated care delivery and performance management. The value chain runs from payer contracts (Medicare Advantage and other value-based arrangements) to patient services delivered through an affiliated practice network. Agilon supplies the operating layer—care management, clinical analytics, utilization guidance, and quality/performance reporting—while physician partners provide the clinical touchpoints. Revenues are generated through contractual economics tied to members attributed to the network and performance against quality and cost benchmarks, with portions of the economics flowing back to practice partners.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly tied to value-based economics rather than pure fee-for-service volume. Key monetisation drivers include:
  • Per-member/per-month (PMPM) or network management fees: recurring stream tied to attributed membership, supporting structural gross margin with scale.
  • Performance-based payments: shared savings and incentive revenue dependent on medical cost performance, utilization management, and quality metrics.
  • Risk arrangement economics (where applicable): contractual arrangements may create exposure to medical cost trend and actuarial assumptions; upside and downside are reflected in profitability through medical cost ratio and reserve discipline.
Primary margin drivers generally include (i) the ability to manage medical cost trend through care management and appropriate utilization, (ii) operating leverage from a growing member base, and (iii) careful contract structuring that balances upside with downside exposure and reimbursement mechanics.

🧠 Competitive Advantages & Market Positioning

Agilon’s moat is rooted in an integrated ecosystem combining (1) an operating layer for care management, (2) a physician-practice network, and (3) performance analytics that improve outcomes and contracting leverage. Moat thesis (hard-to-copy):
  • High switching costs (operational and workflow lock-in): once a practice is integrated into Agilon’s care management workflows, reporting cadence, attribution processes, and performance feedback loops, replacing the enablement layer requires operational re-build and payer contract renegotiation—costly for both practices and payers.
  • Data and execution compounding: longitudinal care management insights improve risk stratification, care pathways, and utilization management, strengthening performance over time and improving the attractiveness of future payer bids.
  • Contracting leverage from demonstrated outcomes: improved quality and cost performance can strengthen renewal prospects and allow for more favorable economics versus less operationally mature competitors.
Competitive benchmarking:
  • Aledade: focuses on enabling independent physician participation in value-based arrangements; the competitive point is network integration and payer-facing execution.
  • Privia Health: builds large physician enablement platforms with value-based contracting and analytics; competes on scale and the ability to operationalize chronic care management.
  • Oak Street Health: delivers value-based care through clinic-based delivery; competes more directly on patient access and care delivery footprint rather than an “enablement” model.
Contrast: Agilon’s emphasis is on integrating physician partners into a coordinated value-based network with an analytics-and-care-management operating layer, whereas some rivals lean more heavily into either clinic ownership models (Oak Street) or broader primary care platform build-out (Privia/Aledade). The market share contest is therefore less about payer relationships alone and more about execution quality, contracting economics, and practice-level retention.

🚀 Multi-Year Growth Drivers

Growth is supported by secular demand for lower-cost, higher-quality care delivery models:
  • Shift from fee-for-service to value-based contracts: payers and employers continue to expand Medicare Advantage and other risk/value arrangements that reward cost and quality performance.
  • Chronic disease burden and aging demographics: increasing utilization needs raise the value of coordinated care, risk stratification, and proactive interventions.
  • Network scale and payer bid participation: expanding attributed membership increases the probability of securing and maintaining contracts with attractive benchmark structures.
  • Practice consolidation into managed networks: independent practices increasingly seek operating support, analytics, and performance infrastructure to compete under value-based contracting.
Over a 5–10 year horizon, the addressable market is driven by the continued adoption of value-based care across Medicare and commercial lines, with durable demand for platforms that can operationalize performance at scale.

⚠ Risk Factors to Monitor

  • Medical cost trend and reimbursement volatility: profitability can be pressured by unexpected utilization, coding/risk mix shifts, or changes in benchmark mechanics.
  • Regulatory and contracting changes: CMS rules, Medicare Advantage policy, and value-based program design can alter economics, attribution methodologies, or quality requirements.
  • Downside risk exposure: where arrangements include downside participation, adverse cost outcomes can impact margins and capital needs.
  • Operational execution risk: care management effectiveness depends on implementation quality—staffing, provider engagement, and adherence to care pathways.
  • Data security and privacy compliance: analytics and care management are dependent on high-integrity data handling under HIPAA and evolving cybersecurity requirements.

📊 Valuation & Market View

Valuation for value-based care platforms typically emphasizes operating metrics rather than purely traditional healthcare multiples:
  • Revenue durability and recurring economics: PMPM/network fees and membership growth influence price-to-sales and EV-based frameworks.
  • Quality of earnings: investors focus on performance-based revenue sustainability, medical cost ratio discipline, and reserve methodology credibility.
  • Operating leverage: scalable care management infrastructure can support margin expansion if medical cost trend is controlled.
  • Contract profile: the mix of upside versus downside participation and the stability of payer contracting terms can move sentiment materially.
In practice, the market tends to reward platforms that demonstrate repeatable contract execution, stable practice retention, and credible risk-adjustment performance over cycle conditions.

🔍 Investment Takeaway

Agilon Health presents a structurally defensible model built on an integrated value-based care ecosystem. The central moat is the compounding effect of care management execution, analytics-driven performance, and practice integration that elevates switching costs for both physician partners and payers. Sustained growth should track the ongoing shift toward value-based contracting and the scaling of attributed membership, tempered by medical cost trend uncertainty and policy/contract design risk.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for AGL.

prnewswire.com2026-07-29

Did agilon health, inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

gurufocus.com2026-07-27

Corebridge Financial Enhances The Power Series of Index Annuities with New Accumulation and Diversification Capabilities

Corebridge Financial today announced the addition of Protected Growth Benefit and preset allocation options to select versions of The Power Series of Index Annu

businesswire.com2026-07-23

Kaskela Law Firm Announces Investigation of Agilon Health, Inc. (AGL) and Encourages Long-Term AGL Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) (“Agilon”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/agilon-health/ Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company's stock between April 15, 2021 and February 27, 2024. According to the complaint, during that.

businesswire.com2026-07-10

agilon health Reports ACO REACH Model Results for 2024 Performance Year

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gross savings (13.6% gross savings rate), including $54 million savings in the Medicare Trust Fund, during the 2024 performance year of the ACO Realizing Equity, Access and Community Health (ACO REACH) model. agilon's eight REACH ACOs operate under full risk, a.

businesswire.com2026-07-07

agilon health Sets Date to Report Second Quarter 2026 Financial Results

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for U.S. participants and +1 (585) 542-9983 for international participants and refe.

zacks.com2026-06-26

Agilon Health (AGL) Is Up 0.79% in One Week: What You Should Know

Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com2026-06-26

Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

seekingalpha.com2026-06-24

agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating

agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.

zacks.com2026-06-23

Is the Options Market Predicting a Spike in agilon health Stock?

Investors need to pay close attention to AGL stock based on the movements in the options market lately.

businesswire.com2026-06-09

agilon health to Participate in Upcoming Conferences

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its management team will participate in investor meetings and industry discussions at the following conferences: Truist Securities Healthcare Disruptors & Digital Health Conference on Tuesday, June 23, 2026 in New York. Management will participate in an ACO Model panel discussion at 1:50pm ET and conduct o.

benzinga.com2026-06-03

These ETFs Owned Russell 2000's Biggest Winners Before They Soared 400%+ In 2026

Investors searching for the biggest stock winners of 2026 may be surprised to learn they already own some of them through small-cap ETFs.

zacks.com2026-05-28

Are You Looking for a Top Momentum Pick? Why Agilon Health (AGL) is a Great Choice

Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com2026-05-27

Are Medical Stocks Lagging Agilon Health (AGL) This Year?

Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.

zacks.com2026-05-27

Despite Fast-paced Momentum, Agilon (AGL) Is Still a Bargain Stock

Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

zacks.com2026-05-11

Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?

Here is how Agilon Health (AGL) and Amarin (AMRN) have performed compared to their sector so far this year.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"AGL reported Q1 2026 revenue of $1.420B and net income of $29.97M (EPS: $1.80). Versus Q4 2025, revenue declined from $1.569B to $1.420B (-9.6% QoQ) and net income swung from a loss (-$188.9M) to a profit (+$300.0M QoQ). Versus Q1 2025, revenue decreased from $1.533B to $1.420B (-7.3% YoY) while net income increased from $12.1M to $30.0M (+147.6% YoY). Profitability improved sharply: Q1 2026 net margin was ~2.1% compared with -12.0% in Q4 2025, indicating strong bottom-line normalization after prior-quarter losses. Operating income also turned positive ($4.0M vs -$155.8M QoQ). Cash flow improved as well: operating cash flow was $23.7M and free cash flow was $20.6M in Q1 2026, compared with -$20.5M operating cash flow and -$37.6M free cash flow in Q4 2025. Balance sheet resilience looks solid in net terms: cash and short-term investments totaled ~$231M and net debt remained negative (~-$110M), though total equity has been volatile across the last few quarters (notably due to retained earnings swings). Shareholder returns are strongly positive based on the provided market data (price $30.05; +449% 1Y), which should materially lift the total return outlook. No dividends were paid."

Revenue Growth

Neutral

Revenue was $1.420B in Q1 2026, down -9.6% QoQ (vs $1.569B in Q4 2025) and -7.3% YoY (vs $1.533B in Q1 2025), indicating a mild top-line contraction despite the turnaround in earnings.

Profitability

Strong

Net income rose to $29.97M in Q1 2026 from -$188.9M in Q4 2025 (+300.0M QoQ) and from $12.1M in Q1 2025 (+147.6% YoY). Net margin improved to ~2.1% from -12.0% QoQ, reflecting strong margin/earnings normalization.

Cash Flow Quality

Good

Operating cash flow improved to $23.7M and free cash flow to $20.6M in Q1 2026, versus operating cash flow -$20.5M and free cash flow -$37.6M in Q4 2025. While no dividends or buybacks were reported, earnings-to-cash improved materially.

Leverage & Balance Sheet

Positive

Net debt remains negative at ~-$110.0M (cash/short-term investments ~ $231M vs total debt ~ $30M), suggesting low leverage risk. However, equity has been volatile across prior quarters (retained earnings swings), so resilience is good on net debt but less consistent in accounting equity.

Shareholder Returns

Excellent

Strong momentum: provided market data shows +449.4% 1Y and +3,013.0% 6M. With no dividend payments shown, the total shareholder return is dominated by capital appreciation, which is exceptionally strong.

Analyst Sentiment & Valuation

Neutral

Consensus target ($24.5) is below the current price ($30.05), implying potential upside is limited versus near-term expectations. Valuation signals appear mixed given the jump in earnings alongside very high recent price momentum.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

AGL delivered a strong Q1 2026 performance, beating the top end of guidance across revenue, medical margin, and adjusted EBITDA, supported by (1) improved member-level visibility from the enhanced data pipeline, (2) better-than-expected risk adjustment driven by an updated 1.5% full-year risk-score increase (vs prior 0.4%), and (3) continued medical margin discipline despite limited early paid-claims visibility. Medical margin rose to $149M and adjusted EBITDA to $54M, with ACO REACH contributing meaningfully ($27M adjusted EBITDA), though management stressed the Q1 ACO REACH beat largely reflected CMS benchmark changes tied to 2025 back-outs (not durable incremental operating momentum). Full-year 2026 guidance was raised to revenue ~$5.7B, medical margin ~$375M, and adjusted EBITDA ~$25M, while maintaining a conservative net cost trend of ~7%. The key question for sustainability is whether clinical pathway scaling (COPD/dementia) and AI-enabled workflows convert to claims-level outcomes in 2026 versus a heavier 2027 benefit window.

AI IconGrowth Catalysts

  • CHF pathway scaling across 90% of markets; inpatient first-diagnosis improved from ~25% to <5%; pharmacy integrated management expanding network-wide with improved guideline-directed therapy trends
  • Scaling COPD and broader lung health pathways through 2026 with earlier COPD identification, expanded lung cancer screenings, and increased advanced diagnostic use
  • Dementia program rollout engagement with structured early-stage pathways and virtual diagnostics to address ~50% undiagnosed dementia patients
  • Generative AI-based insights integrated into clinical workflows to drive earlier physician intervention and improve prediction/forecasting quality
  • Enhanced data pipeline enabling member-level risk scores on ~85% of members and earlier validation of burden-of-illness (BOI) trends

Business Development

  • New payer full-risk contract signed in Q1 2026 in an existing market (modeled breakeven margin for the year; margin in Q1 due to seasonality)
  • CMS impact to 2025 ACO REACH benchmarking: removal of fraudulent urinary catheter and suspect skin substitute costs

AI IconFinancial Highlights

  • Q1 2026 exceeded top end of guidance for total revenue, medical margin, and adjusted EBITDA
  • Revenue: ~$1.42B in Q1 2026 vs $1.53B in Q1 2025; higher-than-expected revenue driven by risk adjustment updates and additional full-risk contract plus strong ACO REACH
  • Medical margin: $149M vs $128M in Q1 2025; exceeded high end of guidance, driven by higher revenue and lower overall medical expenses
  • Adjusted EBITDA: $54M vs $21M in Q1 2025; ACO REACH adjusted EBITDA $27M, ahead of expectations by ~ $5M
  • Risk score outlook: revised full-year estimated increase in risk scores to 1.5% (up from 0.4%), net of V28 impact
  • Medical cost trend: 2025 estimated full-year cost trend improved to 6.2% (from 6.5%); Q1 2026 recorded cost trend at 7.4% due to limited paid claims visibility early in year
  • Full-year 2026 net cost trend maintained at ~7% with conservative reserving
  • ACO REACH upside explained as largely 2025 benchmarking/benchmark changes (CMS back-outs) rather than a forward-looking step-up

AI IconCapital Funding

  • Cash and marketable securities: $303M at quarter-end; off-balance sheet cash: $47M held by ACO entities
  • Year-end cash position still expected to be at least $125M
  • Executed a reverse stock split at end of the quarter (no dollar impact provided in transcript)

AI IconStrategy & Ops

  • Enhanced data pipeline providing validated member-level clinical/claims data and member-level risk scores on ~85% of members; improves earlier identification/validation of trends
  • Improved forecasting/estimation process and better actuarial visibility enabling earlier revenue/medical margin updates
  • AI adoption: generative AI integrated into physician workflows; AI also used in suspecting algorithms and risk stratification
  • Clinical program operations: CHF, dementia, COPD/lung health scaling using structured physician-supported protocols and virtual diagnostics/pharmacy support

AI IconMarket Outlook

  • 2026 updated guidance (midpoint-based): revenue ~$5.7B; medical margin ~$375M; adjusted EBITDA ~$25M
  • Q2 2026 guidance midpoint: revenue $1.45B; medical margin $123M; adjusted EBITDA $20M
  • Full-year 2026 net cost trend outlook maintained at ~7%
  • 2027 payer contracting process beginning; management expects disciplined, profitability-focused approach aligned with shared profitability and durable margin expansion

AI IconRisks & Headwinds

  • Limited paid claims visibility early in 2026 required conservative reserving; Q1 cost trend recorded at 7.4% despite guidance net 7% for full year
  • Part D risk remains a key focus; management emphasized continued progress but highlighted remaining opportunity, including keeping Part D exposure manageable
  • Potential sustainability risk: ACO REACH Q1 upside largely tied to 2025 cost back-outs; management indicated it is early to assume further REACH contribution at the same magnitude
  • Census moderation signals slight improvement but remains early-year; management maintained cost trend outlook prudently

Q&A: Analyst Interest

  • Topic: Why ACO REACH upside didn’t imply raising full-year contribution. Management said the ~$5M Q1 beat came from CMS back-outs of 2025 fraudulent urinary catheter and suspect skin substitute costs, which flowed into benchmark changes. Management emphasized it’s early to forecast incremental REACH performance adjustments for the remainder of 2026.
  • Topic: How AI efficiencies flow through OpEx vs medical/revenue. Management bifurcated AI into OpEx efficiencies versus above-the-line effects. They indicated AI-driven risk stratification and suspect algorithms more directly impact medical costs and revenue. They characterized early OpEx impact as limited, with larger value expected later because healthcare outcome value emerges with lag.
  • Topic: Timing and financial impact of scaling dementia and COPD pathways plus contracting governance. Management reaffirmed the rollout progression for COPD and dementia would add value to 2026 only when it shows up in claims; that requires time, but they expect benefit based on the mature CHF program’s observed results. On governance, they denied focus on physician-group governance changes, framing efforts as payer contracting and shared-value articulation to optimize negotiations.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the AGL Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for AGL.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (AGL)

© 2026 Stock Market Info — Agilon Health, Inc. (AGL) Financial Profile